Stem Cells | Biomarkers Stem Cells
http://youtu.be/go-fEZWPJhY Another stem cell breakthrough next UT Southwestern Researchers Discover Biomarker For Mesenchymal Stromal Cell Function In Huma...
By: Nathan Wei
View post:
Stem Cells | Biomarkers Stem Cells - Video
Embryonic stem cells proved effective in treating visual loss
There could be hope on the horizon for the visually impaired. Recently published research shows the use of embryonic stem cells could help treat people suffering from acquired retina disease....
By: ARIRANG NEWS
View original post here:
Embryonic stem cells proved effective in treating visual loss - Video
International Academy of Cardiology: Dinender K. Singla, M.D.: STEM CELLS FOR CARDIAC REGENERATION
STEM CELLS INDUCED CARDIAC REGENERATION IN DOXORUBICIN INDUCED CARDIOMYOPATHY (Invited Lecture) D. Singla, University of Central Florida, Orlando, FL, USA Presented at the: ...
By: Cardiology Online
Read more here:
International Academy of Cardiology: Dinender K. Singla, M.D.: STEM CELLS FOR CARDIAC REGENERATION - Video
New stem cell discovery helps to treat breast cancer
A group of Chinese scientists have discovered pluripotent stem cells in mammary glands. The discovery may lead to new targeted treatment methods for breast cancer. Their research result was...
By: China View
Read the original:
New stem cell discovery helps to treat breast cancer - Video
Meet the Researcher - Oct. 8, 2014
Researchers in the Center for Regenerative Medicine are studying the use of intraspinal deliver of mesenchymal stem cells (MSCs) to the cerebral spinal fluid of patients with ALS using a dose-escal...
By: Mayo Clinic
More here:
Meet the Researcher - Oct. 8, 2014 - Video
Stem Cells FDA Oversight
Celia Witten, M.D., Ph.D., Director, Office of Cellular, Tissue, Gene Therapy Center for Biologics Evaluation Research, Food Drug Administration (FDA) For more information on the 2014...
By: Alliance for Regenerative Medicine
View post:
Stem Cells & FDA Oversight - Video
UCSD oncologist/researcher Catriona Jamieson is principal investigator for the university's $8 million stem cell grant.
To speed up the quest to bring stem cell therapies to patients, a state agency on Thursday granted $8 million each to three academic medical centers pursuing "translational" work -- UC San Diego, UC Los Angeles and City of Hope in Duarte.
The California Institute for Regenerative Medicine voted 10-1 to fund the "alpha" stem cell clinics, which are intended to bring stem cell treatments to the public.
UC San Diego's proposal supports two stem cell-based clinical trials, both already underway. Catriona Jamieson, an oncologist at the university, is the principal investigator for the grant.
One, a treatment for Type 1 diabetes, was developed by San Diego's ViaCyte. The other, for spinal cord injuries, was developed by Geron of Menlo Park. Geron dropped the trial, but it was picked up by Neuralstem of Germantown, Md. In October, UCSD treated the first patient in the revived trial at the university's Sanford Stem Cell Clinical Center.
The stem cell agency, commonly called CIRM, has focused heavily on basic research since its founding by California voters in 2004. But in recent years, the public has become more anxious to see the fruits of $3 billion in bond money given to the agency reach patients. The "alpha" clinics funded Thursday are part of that effort.
Early optimism that treatments would be quickly available was disappointed, mainly because issues of safety had to be resolved first. Therapies that actually place cells in the body posed new risks, because as living things, cells grow and can migrate. Embryonic stem cells can form tumors. Viacyte and Neuralstem grow replacement tissues from embryonic stem cells, so they needed to show that no unconverted cells would accidentally be introduced into the patient.
Skepticism has also grown over the ethics of CIRM officials, mainly regarding conflicts of interests. Many CIRM board members are chosen from institutions that get funded -- a feature written into the agency by Prop. 71. CIRM has adopted reforms to limit board members from voting in matters where they have conflicts. But CIRM's previous president, Alan Trounson, caused more controversy when he joined the board of CIRM-funded Stemcells Inc, just one week after departing the agency.
CIRM President Randy Mills, who replaced Trounson earlier this year, has tried to quell the controversy with new standards to prevent officials like Trounson from appearing to cash in on their agency role. And he has worked with the governing board to rethink how the agency's remaining funds can be best spent.
CIRM has invested heavily in San Diego stem cell programs, most notably contributing $43 million to a $127 million "collaboratory" building across from the Salk Institute in La Jolla. The Sanford Consortium, as it's called, brings together researchers from five institutions: UCSD, the Salk Institute, The Scripps Research Institute, the Sanford-Burnham Medical Research Institute and the La Jolla Institute for Allergy & Immunology.
See the rest here:
UCSD, other stem cell clinics get millions
Contact Information
Available for logged-in reporters only
Newswise In a first-of-its-kind collaboration, the University of California, Los Angeles, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and University of California, Irvine Sue & Bill Gross Stem Cell Research Center received a five year $8M grant from the California Institute of Regenerative Medicine (CIRM), the states stem cell agency, to establish a CIRM Alpha Stem Cell Clinic center of excellence to conduct clinical trials for investigational stem cell therapies and provide critical resources and expertise in clinical research.
The $8M grant was one of three awarded today by CIRM as part of the CIRM Alpha Stem Cell Clinics (CASC) Network Initiative. The joint UCLA/UCI award under the direction of Dr. John Adams, a member of the UCLA Broad Stem Cell Research Center and professor in the department of orthopaedic surgery, will accelerate the implementation of clinical trials and delivery of stem cell therapies by providing world-class, state-of-the-art infrastructure to support clinical research.
CIRM grant reviewers lauded the UCLA/UCI Consortiums impressive and multidimensional team of experienced personnel that will expand access to patients, attracting national and international clinical trials and accelerating future trials in the pipeline.
The initial stem cell trials supported by the UCLA/UCI Alpha Stem Cell Clinic will be two UCLA projects using blood forming stem cells. The first trial will test a stem cell-based gene therapy for patients with bubble baby disease, also called severe combined immune deficiency (SCID), in which babies are born without an immune system. Under the direction of Dr. Donald Kohn, the clinical trial will use the babys own stem cells with an inserted gene modification to correct the defect and promote the creation of an immune system. The second clinical trial, under the direction of Dr. Antoni Ribas, will use patients own genetically modified blood-forming stem cells to engineer and promote an immune response to melanoma and sarcomas.
This CIRM Alpha Stem Cell Clinic grant is an important acknowledgement of our cutting-edge research and will help us to advance the design, testing and delivery of effective and safe stem cell-based therapies, said Dr. Owen Witte, professor and director of the Broad Stem Cell Research Center. The implementation of a standard of excellence in clinical research will improve healthcare and the lives of patients far beyond the longevity of individual trials.
Operating as part of the larger state-wide CIRM supported network, Alpha Stem Cell Clinics provide critical operational support to conduct clinical trials, with focused resources and expertise in stem cell-based clinical research including clinical operations support and patient care coordination personnel.
UCI has established a strong preclinical stem cell research program, and its vital to move ahead to the clinical testing phase, said Sidney Golub, director of UCIs Sue & Bill Gross Stem Cell Research Center. To advance treatments in this field, we all have to work together, and thats what the UCLA-UCI Alpha Stem Cell Clinic program represents.
About the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
Read the original here:
UCLA and UCI Awarded $8M Grant to Launch Collaborative Stem Cell Clinic "Center of Excellence"
Osiris - Company Presentation
Presented by: Lode Debrabandere, Ph.D., CEO Through over 20 years of research, experience and understanding, Osiris Therapeutics has led the way in mesenchymal stem cell (MSC) science and ...
By: Alliance for Regenerative Medicine
Visit link:
Osiris - Company Presentation - Video
Lip Augmentation Using Fat Stem Cells
By: Regenix Clinics
MIAMI (PRWEB) October 22, 2014
More than 900 physicians researchers and regenerative medicine experts from around the world attended the First International Symposium on Stem Cells and Regenerative Medicine, held in Buenos Aires, Argentina Oct. 2-4, 2014.
The event, hosted by Global Stem Cells Group in partnership with Julio Ferreira, M.D., President of the South American Academy Cosmetic Surgery, offered an opportunity for many of the worlds most respected authorities on stem cell and regenerative medicine to showcase advancements in research and therapies on a global level.
An interdisciplinary team of leading international stem cell experts provided a full day of high-level scientific lectures geared to medical professionals. Pioneers and luminaries in stem cell medicine who served as featured speakers at the event included:
Lord David Harrell, PhD., a scientific leader recognized nationally, internationally recognized expert in neuroscience and regenerative medicine and a member of the Global Stem Cells Group Advisory Board spoke on spoke on the cellular composition of bone marrow with a focus on stem and progenitor cell activities of bone marrow stem and progenitor cells.
Joseph Purita, M.D., Director of The Institute of Regenerative and Molecular Orthopedics in Boca Raton, Florida, member of the Global Stem Cells Group Advisory Board and a pioneer in the use of stem cells and platelet rich plasma for a variety of orthopedic conditions, spoke about the use of PRP and stem cell injections for treatment of musculoskeletal conditions. He detailed cutting-edge treatments he now offers to his clinic patients, including extensive use of platelet-rich plasma in conjunction with bone marrow stem cells (BMAC), adipose stem cells (SVF) and fat grafts.
Vasilis Paspaliaris, M.D., CEO of Adistem, Ltd., a member of the Global Stem Cells Group Advisory Board and a thought-leading and highly experienced clinical pharmacologist and medical scientist discussed the proven differences in efficacy between the mesenchyme stem cells (MSCs) of a young donor and those of an aging donor, primarily due to the younger donor cells ability to secrete more trophic factors.
According to Benito Novas, Global Stem Cells Group CEO, the world-class event was well received at a time when the field of regenerative medicine is on the verge of changing medical science forever.
We wanted the symposium to help clear up old misconceptions and change outdated attitudes by educating people on the wide range of illnesses and injuries stem cell therapies are already treating and curing, Novas says. We set out to establish a dialogue between researchers and practitioners in order to help move stem cell therapies from the lab to the physicians office and I believe we achieved our goals with this symposium.
Our objective is to open a dialogue among the worlds medical and scientific communities in order to advance stem cell technologies and translate them into point-of-care medical practices.
Link:
More than 900 Physicians Converge on Buenos Aires for ...
MIAMI (PRWEB) October 22, 2014
More than 900 physicians researchers and regenerative medicine experts from around the world attended the First International Symposium on Stem Cells and Regenerative Medicine, held in Buenos Aires, Argentina Oct. 2-4, 2014.
The event, hosted by Global Stem Cells Group in partnership with Julio Ferreira, M.D., President of the South American Academy Cosmetic Surgery, offered an opportunity for many of the worlds most respected authorities on stem cell and regenerative medicine to showcase advancements in research and therapies on a global level.
An interdisciplinary team of leading international stem cell experts provided a full day of high-level scientific lectures geared to medical professionals. Pioneers and luminaries in stem cell medicine who served as featured speakers at the event included:
Lord David Harrell, PhD., a scientific leader recognized nationally, internationally recognized expert in neuroscience and regenerative medicine and a member of the Global Stem Cells Group Advisory Board spoke on spoke on the cellular composition of bone marrow with a focus on stem and progenitor cell activities of bone marrow stem and progenitor cells.
Joseph Purita, M.D., Director of The Institute of Regenerative and Molecular Orthopedics in Boca Raton, Florida, member of the Global Stem Cells Group Advisory Board and a pioneer in the use of stem cells and platelet rich plasma for a variety of orthopedic conditions, spoke about the use of PRP and stem cell injections for treatment of musculoskeletal conditions. He detailed cutting-edge treatments he now offers to his clinic patients, including extensive use of platelet-rich plasma in conjunction with bone marrow stem cells (BMAC), adipose stem cells (SVF) and fat grafts.
Vasilis Paspaliaris, M.D., CEO of Adistem, Ltd., a member of the Global Stem Cells Group Advisory Board and a thought-leading and highly experienced clinical pharmacologist and medical scientist discussed the proven differences in efficacy between the mesenchyme stem cells (MSCs) of a young donor and those of an aging donor, primarily due to the younger donor cells ability to secrete more trophic factors.
According to Benito Novas, Global Stem Cells Group CEO, the world-class event was well received at a time when the field of regenerative medicine is on the verge of changing medical science forever.
We wanted the symposium to help clear up old misconceptions and change outdated attitudes by educating people on the wide range of illnesses and injuries stem cell therapies are already treating and curing, Novas says. We set out to establish a dialogue between researchers and practitioners in order to help move stem cell therapies from the lab to the physicians office and I believe we achieved our goals with this symposium.
Our objective is to open a dialogue among the worlds medical and scientific communities in order to advance stem cell technologies and translate them into point-of-care medical practices.
PUBLIC RELEASE DATE:
22-Oct-2014
Contact: David McKeon dmckeon@nyscf.org 212-365-7440 New York Stem Cell Foundation @nyscf
NEW YORK, NY (October 22, 2014) The New York Stem Cell Foundation (NYSCF) Research Institute, through the launch of its repository in 2015, will provide for the first time the largest-ever number of stem cell lines available to the scientific research community. Initially, over 600 induced pluripotent stem (iPS) cell lines and 1,000 cultured fibroblasts from over 1,000 unique human subjects will be made available, with an increasing number available in the first year. To collect these samples, NYSCF set up a rigorous human subjects system that protects patients and allows for the safe and anonymous collection of samples from people interested in participating in research.
A pilot of over 200 of NYSCF's iPS cell lines is already searchable on an online database. The pilot includes panels of iPS cell lines generated from donors affected by specific diseases such as type 1 diabetes, Parkinson's disease, and multiple sclerosis, as well as a diversity panel of presumed healthy donors from a wide range of genetic backgrounds representing the United States Census. These panels, curated to provide ideal initial cohorts for studying each area, include subjects ranging in age of disease onset, and are gender matched. Other panels that will be available in 2015 include Alzheimer's disease, schizophrenia, Juvenile Batten disease, and Charcot-Marie-Tooth disease.
"NYSCF's mission is to develop new treatments for patients. Building the necessary infrastructure and making resources available to scientists around the world to further everyone's research are critical steps in accomplishing this goal," said Susan L. Solomon, CEO of The New York Stem Cell Foundation.
NYSCF has developed the technology needed to create a large collection of stem cell lines representing the world's population. This platform, known as the NYSCF Global Stem Cell ArrayTM, is an automated robotic system for stem cell production and is capable of generating 200 iPS cell lines a month from patients with various diseases and conditions and from all genetic backgrounds. The NYSCF Global Stem Cell ArrayTM is also used for stem cell differentiation and drug screening.
Currently available in the online database that was developed in collaboration with eagle-i Network, of the Harvard Catalyst, is a pilot set of approximately 200 iPS cell lines and related information about the patients. This open source, open access resource discovery platform makes the cell lines and related information available to the public on a user-friendly, web-based, searchable system. This is one example of NYSCF's efforts to reduce duplicative research and enable even broader collaborative research efforts via data sharing and analysis. NYSCF continues to play a key role in connecting the dots between patients, scientists, funders, and outside researchers that all need access to biological samples.
"The NYSCF repository will be a critical complement to other existing efforts which are limited in their ability to distribute on a global scale. I believe that this NYSCF effort wholly supported by philanthropy will help accelerate the use of iPS cell based technology," said Dr. Mahendra Rao, NYSCF Vice President of Regenerative Medicine.
To develop these resources, NYSCF has partnered with over 50 disease foundations, academic institutions, pharmaceutical companies, and government entities, including the Parkinson's Progression Markers Initiative (PPMI), PersonalGenomes.org, the Beyond Batten Disease Foundation, among several others. NYSCF also participates in and drives a number of large-scale multi stakeholder initiatives including government and international efforts. One such example is the Cure Alzheimer's Fund Stem Cell Consortium, a group consisting of six institutions, including NYSCF, directly investigating, for the first time, brain cells in petri dishes from individual patients who have the common sporadic form of Alzheimer's disease.
Originally posted here:
The New York Stem Cell Foundation Research Institute announces largest-ever stem cell repository
Contact Information
Available for logged-in reporters only
Newswise Scientists have described a way to convert human skin cells directly into a specific type of brain cell affected by Huntingtons disease, an ultimately fatal neurodegenerative disorder. Unlike other techniques that turn one cell type into another, this new process does not pass through a stem cell phase, avoiding the production of multiple cell types, the studys authors report.
The researchers, at Washington University School of Medicine in St. Louis, demonstrated that these converted cells survived at least six months after injection into the brains of mice and behaved similarly to native cells in the brain.
Not only did these transplanted cells survive in the mouse brain, they showed functional properties similar to those of native cells, said senior author Andrew S. Yoo, PhD, assistant professor of developmental biology. These cells are known to extend projections into certain brain regions. And we found the human transplanted cells also connected to these distant targets in the mouse brain. Thats a landmark point about this paper.
The work appears Oct. 22 in the journal Neuron.
The investigators produced a specific type of brain cell called medium spiny neurons, which are important for controlling movement. They are the primary cells affected in Huntingtons disease, an inherited genetic disorder that causes involuntary muscle movements and cognitive decline usually beginning in middle-adulthood. Patients with the condition live about 20 years following the onset of symptoms, which steadily worsen over time.
The research involved adult human skin cells, rather than more commonly studied mouse cells or even human cells at an earlier stage of development. In regard to potential future therapies, the ability to convert adult human cells presents the possibility of using a patients own skin cells, which are easily accessible and wont be rejected by the immune system.
To reprogram these cells, Yoo and his colleagues put the skin cells in an environment that closely mimics the environment of brain cells. They knew from past work that exposure to two small molecules of RNA, a close chemical cousin of DNA, could turn skin cells into a mix of different types of neurons.
In a skin cell, the DNA instructions for how to be a brain cell, or any other type of cell, is neatly packed away, unused. In past research published in Nature, Yoo and his colleagues showed that exposure to two microRNAs called miR-9 and miR-124 altered the machinery that governs packaging of DNA. Though the investigators still are unraveling the details of this complex process, these microRNAs appear to be opening up the tightly packaged sections of DNA important for brain cells, allowing expression of genes governing development and function of neurons.
See the article here:
Human Skin Cells Reprogrammed Directly Into Brain Cells
Bone Marrow-Derived Stem Cell Prolotherapy
Stem Cell Prolotherapy is a procedure in which adult mesenchymal stem cells are transplanted directly into the damaged tissue or injury and promotes healing. Stem cells are the repairmen...
By: Kab S. Hong M.D.
See the original post here:
Bone Marrow-Derived Stem Cell Prolotherapy - Video
Do I Need PRP/PRF/PDGF/BMP For Dental Implants and Bone grafts?
http://www.burbankdentalimplants.com/blog/ In this video, I described what is PRP and PRF and how to concentrate growth factors, stem cells and molecular enhancers made from your own blood...
By: Ramsey Amin
Read this article:
Do I Need PRP/PRF/PDGF/BMP For Dental Implants and Bone grafts? - Video
Stem Cells, Regenerative Medicine and Policy Impediments to the New Future
Oct. 21, 2014 Baker Institute nonresident scholar Deepak Srivastava explores the current and future potential of stem cells and regenerative medicine.
By: BakerInstitute
See original here:
Stem Cells, Regenerative Medicine and Policy Impediments to the New Future - Video
PUBLIC RELEASE DATE:
20-Oct-2014
Contact: David McKeon 212-365-7440 New York Stem Cell Foundation @nyscf
Leaders in translational stem cell research from around the world will present the latest advances in stem cell science that are leading to better treatments and cures to disease and injury at The New York Stem Cell Foundation's Ninth Annual Translational Stem Cell Research Conference.
The opening day of the conference includes a panel discussion on large scale, big data stem cell and genetic initiatives moderated by Susan L. Solomon, JD, CEO and Co-founder of The New York Stem Cell Foundation (NYSCF), with panelists George Church, PhD, Harvard Medical School; John Greally, PhD, Albert Einstein College of Medicine; Scott Noggle, PhD, The NYSCF Research Institute; and Eric Schadt, PhD, the Icahn School of Medicine at Mount Sinai.
Later that day, a discussion on neurodegeneration includes Kevin Eggan, PhD, Harvard University and the NYSCF Research Institute, who will discuss his research identifying an existing drug candidate that may be of use treating ALS and is entering clinical trials in the coming year. The following session on cell reprogramming and cancer includes Michael Milone, MD, PhD, University of Pennsylvania, who will discuss recent research results from his lab and his colleagues including the results of a clinical trial for leukemia featured in The New York Times last week. The first day closes with a conversation on personalized medicine featuring Dieter Egli, PhD, NYSCF Robertson Investigator at the NYSCF Research Institute and Columbia University; Rudolf Jaenisch, MD, The Whitehead Institute; and Sir Ian Wilmut, FRS, FRSE, University of Edinburgh.
On October 23, the day will begin with remarks by Kenneth Adams and Kyle Kimball, President of the Empire State Development Corporation and President of the New York City Economic Development Corporation, respectively. The session on translating innovation from the laboratory to the clinic features Stephen Chang, PhD, of the NYSCF Research Institute and Richard Pearse, PhD, of the Harvard Catalyst and eagle-i Network who will discuss their collaboration on the first publicly available induced pluripotent stem cell database. The day will close with a presentation on induced neuronal cells and cell transdifferentiation from the 2014 NYSCF Robertson Stem Cell Prize recipient, Marius Wernig, MD, PhD, of Stanford University School of Medicine.
Sir Ian Wilmut will give the keynote address on October 22nd and Dr. Rudolf Jaenisch will give the keynote address on the last day of the conference.
The full conference agenda can be found at http://www.nyscf.org/conference
###
See the original post:
Stem cell and clinical research advances to be presented at NYSCF's Ninth Annual Conference
La Jolla, CA (PRWEB) October 21, 2014
StemGenex, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases today announced their newest clinical study in partnership with Stem Cell Research Centre for Osteoarthritis. StemGenex and Stem Cell Research Centre (SCRC) believe that a commitment to the safety and efficacy of stem cell therapy are paramount when providing care to patients with life threatening diseases.
There are currently 21 million people in the U.S. alone, who suffer from Osteoarthritis. The most common symptoms are joint pain and stiffness which most commonly affect the neck, lower back, knees, shoulders and hips. These symptoms gradually worsen over time ultimately leading to the need for a total joint replacement procedure. StemGenex believe their new clinical study may provide patients improved mobility, significantly reduced pain and ultimately a better quality of life without needing joint replacement surgery.
This clinical study makes stem cell therapy for osteoarthritis accessible to the millions of individuals currently struggling with this painful disease. The protocol used in these stem cell treatments is unique to StemGenex and SCRC, having the possibility of being more effective than other stem cell treatments currently available. These treatments will utilize a multiple administration method which also includes injections precisely targeting the joint space. StemGenex believes these treatments may be able to keep patients from needing joint replacement surgery in the future, due to regeneration of cartilage in the joint.
This clinical study will be conducted under the leadership of the principal investigator,Dr. Jeremiah McDole, Ph.D. Dr. McDole states, We are excited to begin enrolling for this new study. We have high expectations for what we will learn and what advancements can ultimately be implemented. Of course, our focus is always set toward the near future and what can be done to help improve the lives of those individuals with Osteoarthritis.
This study is registered through The National Institutes of Health which can be found at http://www.clinicaltrials.gov and is being conducted under IRB approval of Stem Cell Research Centre (SCRC). There are many patients who are exploring stem cell therapy for osteoarthritis and it is important they have access to top-tier stem cell therapy. By providing patients access to stem cell studies registered through The National Institutes of Health, patients now have the ability to choose treatment that focuses on both safety and efficacy.
Rita Alexander, founder and president of StemGenex stated With so many people suffering from Osteoarthritis its absolutely wonderful to provide a treatment that has not only shown efficacy but also to be minimally invasive. Over the last several years we have observed significant improvement in the symptoms of Osteoarthritis patients through stem cell treatment. Through these registered clinical studies, we will now be able to publish our findings over the next few years.
This clinical study follows on the heels of StemGenex latest clinical studies for both Parkinsons disease and Multiple Sclerosis. Stem cell treatment studies are currently being offered by StemGenex partnering with Stem Cell Research Centre (SCRC) to patients diagnosed with Osteoarthritis as well as degenerative neurological diseases. StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative conditions including Multiple Sclerosis, Alzheimers disease, stroke recovery and others.
To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact@stemgenex.com
Stem Cell Hair Therapy - Hair Regrowth Treatment using Adult Stem Cell from Luminesce
Do It Yourself - Stem Cell Hair Therapy : http://placesiana.com/stem-cell-hair-loss-therapy Imagine becoming a healthier, much younger, better looking you? Infused with a potent growth factor...
By: Sam Jeunesse
Read more from the original source:
Stem Cell Hair Therapy - Hair Regrowth Treatment using Adult Stem Cell from Luminesce - Video